Skip to main content

Table 2 Allele frequencies and genotype distribution of CD160 polymorphisms in AITD patients and controls

From: Associations between CD160 polymorphisms and autoimmune thyroid disease: a case-control study

Gene/SNP Controls AITD P value GD P-Value HT P value
CD160 n (%) n (%) AITD vs. Control n (%) GD vs. Control n (%) HT vs. Control
rs744877
 A 1130 (66%) 1399 (68.78%) 0.071 885 (69.69%) 0.034 514 (67.10%) 0.593
 C 582 (34%) 635 (31.22%) 385 (30.31%) 252 (32.90%)
 AA 361 (42.17%) 487 (47.89%) 0.031 314 (49.53%) 0.014 173 (45.17%) 0.464
 AC 408 (47.66%) 425 (41.79%) 257 (40.54%) 168 (43.86%)
 CC 87 (10.17%) 105 (10.32%) 63 (9.93%) 42 (10.97%)
rs3766526
 G 1406 (82.13%) 1636 (80.43%) 0.186 1013 (79.89%) 0.123 623 (81.33%) 0.635
 A 306 (17.87%) 398 (19.57%) 255 (20.11%) 143 (18.67%)
 GG 574 (67.06%) 659 (64.80%) 0.319 407 (64.20%) 0.187 252 (65.80%) 0.888
 GA 258 (30.14%) 318 (31.27%) 199 (31.39%) 119 (31.07%)
 AA 24 (2.80%) 40 (3.93%) 28 (4.41%) 12 (3.13%)
  1. AITD autoimmune diseases, GD Graves’ disease, HT Hashimoto’s thyroiditis